Neuroendocrine Tumor
📧 Sign up to get email alerts when something new happens for Neuroendocrine Tumor.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-07-27Clinical Trial Update: Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres [Phase 2]
Phase 2 trial investigating lanreotide in metastatic gastrointestinal neuroendocrine tumors undergoing liver-directed radioembolization.
-
CLINICAL_TRIALS trial_result · 2023-06-27Clinical Trial Update: Neoadjuvant PRRT With 177Lu-DOTATATE Followed by Surgery for Resectable PanNET [Phase 2]
Phase 2 trial update on neoadjuvant PRRT with 177Lu-DOTATATE followed by surgery for resectable pancreatic neuroendocrine tumors (PanNET).
-
CLINICAL_TRIALS trial_result · 2023-03-30Clinical Trial Update: Phase III Study of Surufatinib in Treating Advanced Pancreatic Neuroendocrine Tumors [Phase 3]
Phase III study results for surufatinib in advanced pancreatic neuroendocrine tumors completed.
-
FDA approval · 2023-03-15FDA Approved: ILLUCCIX — Supplemental Application (Telix Pharmaceuticals (US) Inc.)
FDA approved a supplemental application for ILLUCCIX, a kit for preparing Gallium-68 gozetotide injection used in PET imaging of neuroendocr…
-
FDA approval · 2023-03-07FDA Approved: LUTATHERA — Supplemental Application (Advanced Accelerator Applications USA, Inc)
FDA approved a supplemental application for LUTATHERA (lutetium Lu-177 dotatate) submitted by Advanced Accelerator Applications USA, Inc. Th…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2022-12-22Clinical Trial Update: Imaging of Patients With Known or Suspected Somatostatin Receptor Positive Neuroendocrine Tumors Using Cu64-DOTATATE [Phase 3]
Phase 3 trial assessing Cu64-DOTATATE imaging in patients with known or suspected somatostatin receptor–positive neuroendocrine tumors has c…
-
CLINICAL_TRIALS trial_result · 2022-11-25Clinical Trial Update: Multi-cohort Study of Surufatinib Plus Sintilimab in Metastatic NEN and Pancreatic Carcinoma Who Failed Standard Chemotherapy [Phase 2]
Phase 2 trial evaluating surufatinib plus sintilimab in metastatic neuroendocrine tumors and pancreatic carcinoma after failure of standard …
-
CLINICAL_TRIALS trial_result · 2022-11-08Clinical Trial Update: Intra-arterial Lutetium-177-dotatate for Treatment of Patients With Neuro-endocrine Tumor Liver Metastases [Phase 2, Phase 3]
A clinical trial update for intra-arterial Lutetium-177-dotatate in neuroendocrine tumor patients with liver metastases (Phase 2 and Phase 3…
-
CLINICAL_TRIALS trial_result · 2022-11-03Clinical Trial Update: Evaluating an Amino Acid Based Medical Food w/ Diarrhea in Carcinoid Syndrome & Other NETs [Phase 2]
Phase 2 clinical trial update evaluating an amino acid–based medical food for diarrhea in neuroendocrine tumors, including carcinoid syndrom…
-
FDA approval · 2022-06-13FDA Approved: LUTATHERA — Supplemental Application (Advanced Accelerator Applications USA, Inc)
FDA approved a supplemental application for LUTATHERA (Lutetium-177 dotatate) from Advanced Accelerator Applications USA, Inc. The action re…
-
FDA approval · 2022-06-06FDA Approved: LUTATHERA — Supplemental Application (Advanced Accelerator Applications USA, Inc)
FDA approves a supplemental application for LUTATHERA (Lutetium Lu-177 dotatate) filed by Advanced Accelerator Applications USA, Inc.
-
CLINICAL_TRIALS trial_result · 2022-02-17Clinical Trial Update: Al18F-NOTA-octreotide PET Imaging in Neuroendocrine Tumors [Phase 2, Phase 3]
Phase 2/3 trial investigating Al18F-NOTA-octreotide PET imaging for neuroendocrine tumors has completed.
-
CLINICAL_TRIALS trial_result · 2022-01-18Clinical Trial Update: Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs) [Phase 2]
Phase 2 trial evaluation of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid tumors has compl…
-
FDA approval · 2021-12-22FDA Approved: GA-68-DOTATOC — Supplemental Application (UIHC P E T Imaging Center)
FDA approved a supplemental application for GA-68-DOTATOC (edotreotide gallium-68) for PET imaging, enabling its use in neuroendocrine tumor…
-
FDA approval · 2021-12-22FDA Approved: DETECTNET — Supplemental Application (CURIUM US LLC)
FDA approved a supplemental application for DETECTNET, a copper-64 DOTATATE PET imaging agent from Curium US LLC.
-
FDA approval · 2021-12-22FDA Approved: OCTREOSCAN — Supplemental Application (Curium US LLC)
The FDA approved a supplemental application for OCTREOSCAN (Indium-111 pentetreotide) submitted by Curium US LLC.
-
CLINICAL_TRIALS trial_result · 2021-12-21Clinical Trial Update: Gallium-68 Labeled LM3 PET/CT in Neuroendocrine Tumors [Phase 1, Phase 2]
Clinical trial updates for Gallium-68 labeled LM3 PET/CT in neuroendocrine tumors across Phase 1 and Phase 2, completed.
-
CLINICAL_TRIALS trial_result · 2021-11-24Clinical Trial Update: Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm [Phase 2]
Phase 2 trial evaluating chidamide plus sintilimab in chemotherapy-refractory advanced high-grade neuroendocrine neoplasm; status not yet de…
-
CLINICAL_TRIALS trial_result · 2021-09-22Clinical Trial Update: Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT [Phase 2]
Phase 2 trial comparing Ga-DOTATOC PET sensitivity to Octreoscan SPECT+CT in medulloblastoma and related neuroendocrine tumors; results post…
-
CLINICAL_TRIALS trial_result · 2021-09-05Clinical Trial Update: A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NET [Phase 2]
A Phase 2 trial is investigating the safety and activity of combining cabozantinib with lanreotide in metastatic well-differentiated neuroen…
-
CLINICAL_TRIALS trial_result · 2021-08-02Clinical Trial Update: Pharmaco-immunological Study of Interferon-alpha and Metronomic Cyclophosphamide Association in Neuroendocrine Tumors [Phase 2]
Phase 2 trial update on combining interferon-alpha with metronomic cyclophosphamide in neuroendocrine tumors has completed recruitment.
-
CLINICAL_TRIALS trial_result · 2021-03-09Clinical Trial Update: A Study of Pembrolizumab in Patients With Neuroendocrine Tumors [Phase 2]
Phase 2 trial of pembrolizumab in patients with neuroendocrine tumors has completed; results posted in 2021.
-
CLINICAL_TRIALS trial_result · 2020-11-05Clinical Trial Update: Impact of Peptides and Chelators on Somatostatin Receptor Antagonists [Phase 2]
Phase 2 clinical trial update evaluating the impact of peptides and chelators on somatostatin receptor antagonists for neuroendocrine tumors…
-
CLINICAL_TRIALS trial_result · 2020-10-28Clinical Trial Update: Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study [Phase 2]
A Phase II investigator-initiated trial evaluating safety and tolerability of everolimus as second-line therapy in poorly differentiated neu…
-
CLINICAL_TRIALS trial_result · 2020-09-29Clinical Trial Update: RAD001 and Erlotinib in Patients With Neuroendocrine Tumors [Phase 2]
Phase 2 trial investigating RAD001 ( everolimus ) and erlotinib in patients with neuroendocrine tumors; study terminated with results posted…